Illumina (ILMN) : Wellington Shields reduced its stake in Illumina by 0.13% during the most recent quarter end. The investment management company now holds a total of 149,223 shares of Illumina which is valued at $21.5 Million after selling 195 shares in Illumina , the firm said in a disclosure report filed with the SEC on May 26, 2016.Illumina makes up approximately 13.99% of Wellington Shields’s portfolio.
Other Hedge Funds, Including , Springbok Capital Management sold out all of its stake in ILMN during the most recent quarter. The investment firm sold 1,969 shares of ILMN which is valued $276,664.Rainier Investment Management boosted its stake in ILMN in the latest quarter, The investment management firm added 14,960 additional shares and now holds a total of 39,100 shares of Illumina which is valued at $5.5 Million. Illumina makes up approx 0.25% of Rainier Investment Management’s portfolio.Philadelphia Trust Co boosted its stake in ILMN in the latest quarter, The investment management firm added 871 additional shares and now holds a total of 13,575 shares of Illumina which is valued at $1.9 Million. Illumina makes up approx 0.16% of Philadelphia Trust Co’s portfolio.Gerstein Fisher reduced its stake in ILMN by selling 204 shares or 11.79% in the most recent quarter. The Hedge Fund company now holds 1,526 shares of ILMN which is valued at $208,940. Illumina makes up approx 0.03% of Gerstein Fisher’s portfolio.
Illumina opened for trading at $144.42 and hit $146.46 on the upside on Wednesday, eventually ending the session at $145.78, with a gain of 0.66% or 0.95 points. The heightened volatility saw the trading volume jump to 7,86,963 shares. Company has a market cap of $21,459 M.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Shares were Reiterated by Mizuho on May 4, 2016 to “Neutral” and Lowered the Price Target to $ 138 from a previous price target of $150 .Shares were Reiterated by Stifel on May 4, 2016 to “Buy” and Lowered the Price Target to $ 160 from a previous price target of $215 .Shares were Reiterated by Canaccord Genuity on May 4, 2016 to “Hold” and Lowered the Price Target to $ 140 from a previous price target of $160 .
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.